Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

Medicines

Selecting patients for idarucizumab (Praxbind)

Wednesday, 2 Nov 2016

In the final video of the series Professor Pollack takes us through interim results from RE-VERSE AD which identified the types of patients suitable for dabigatran reversal with idarucizumab (Praxbind).

Already a member?

Login to keep reading.

Email me a login link

Not a member yet?

Join now to stay up to date with the latest clinical and medico-political news relevant to your specialty. the limbic is intended for practicing healthcare professionals only.

title*

first name*

last name*

country*

Postcode where you practice*

Email*

password* Forgot password?

Password must contain at least 8 characters including 1 letter and 1 number.

ahpra number* Find my AHPRA number

primary area of interest*

Our newsletter is a quick and easy to read summary of the latest clinical and medico-political news relevant to your specialty. It may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government agencies and not-for-profit organisations. Your details will not be shared with any other party.

I would like to receive the limbic newsletter

I have read and agree to the limbic Terms and Conditions & Privacy Policy

Cancel

Selecting patients for idarucizumab (Praxbind)

Already a member?

Not a member yet?

Selecting patients for idarucizumab (Praxbind)